Image courtesy of Abbott

Abbott Receives FDA Emergency use Authorization and Launches Test to Detect Novel Coronavirus

Originally posted on Abbott.com

– The test will be used on the company’s m2000 RealTime system that is currently available in hospitals and molecular laboratories in the U.S.

– Abbott shipping 150,000 laboratory tests immediately; tests already sent to hospital and academic medical center labs in 18 states including Illinois, California, New York, Massachusetts and Washington

– Company scaling up production at its U.S. manufacturing location to reach capacity for 1 million tests per week by end of March

Abbott announced today that the U.S. Food and Drug Administration has issued Emergency Use Authorization (EUA) for the company’s molecular test for novel coronavirus (COVID-19). Abbott is immediately shipping 150,000 Abbott RealTime SARS-CoV-2 EUA tests to existing customers in the U.S. The tests are used on the company’s m2000™ RealTime System. Abbott will be working with health systems and government authorities to deploy additional m2000 systems where they are needed.

“A global challenge like coronavirus requires the commitment and cooperation of everyone who has the ability to help address it,” said Miles D. White, chairman and chief executive officer, Abbott. “I’m proud of the Abbott team and what they’ve accomplished in such a short period of time, and I want to thank the Administration and the FDA for their partnership in making this happen.”

Accelerating testing to help combat the pandemic
As a leader in diagnostics testing, Abbott is working to do its part to combat this global pandemic. Across the U.S., more than 175 m2000 systems are used in hospital and reference laboratories. The systems have the ability to run high volumes of up to 470 tests in 24 hours, helping to meet the increasing demand for testing. Many of these instruments are used in university and community hospitals where patients come for care, resulting in testing that happens closer to the patient rather than sending it to an offsite lab. Abbott is immediately distributing 150,000 tests and will continue ramping up production to the highest levels possible, with the goal of providing up to 1 million tests per week. Abbott is manufacturing these tests in the U.S.

 

Latest News

Kaiser Permanente Mental Health App Now Available to Members at No Cost

Originally published on about.kaiserpermanente.org.  myStrength app is part of Kaiser Permanente’s effort to provide valuable tools to support mental and emotional health, particularly during stressful times. As part of its commitment to offer members innovative ways to promote personal health and wellness, particularly during increasing levels of stress and anxiety,…

AT&T Believing in our COVID-19 First Responders

Originally posted on ATT.com AT&T supports first responders, medical personnel, responding to COVID-19 with nourishing meals  Across the country – and around the world – first responders and medical personnel are playing a critical role in helping care for their communities during the COVID-19 crisis. “First responders and medical personnel…

Humana Announces Health Care Provider Initiative to Help Ease Financial and Administrative Stress During Coronavirus Pandemic

Originally posted on Humana.com Leading health and well-being company Humana Inc., announced actions designed to help provide financial and administrative relief for the health care provider community facing unprecedented strain during the coronavirus pandemic. First, Humana is implementing simplified and expedited claims processing, in order to get reimbursement payments to providers…

hershey

The Hershey Company: Togetherness During Uncertain Times

Originally published on thehersheycompany.com by Thomas Smuda, Vice President, Retail Staying true to our purpose, to make more moments of goodness, and to our values is important in uncertain times We’re making safety-first decisions for employees while still helping retailers maintain local food supply Hershey’s culture and spirit of connections…